Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer

Core Insights - Oculis Holding AG has appointed Daniel S. Char as Chief Legal Officer, enhancing its leadership team as the company progresses its late-stage pipeline and prepares for commercialization [1][2] - The appointment aligns with Oculis' strategic plan to advance its innovative pipeline, particularly focusing on OCS-01, the first topical eye drop for retina treatment [2] - Mr. Char brings over 35 years of legal experience in biotech, having held senior positions at various companies, including ImmunoGen and Evelo Biosciences [2] Company Overview - Oculis is a global biopharmaceutical company focused on saving sight and improving eye care, with a differentiated pipeline of innovative product candidates [3] - Key products in development include OCS-01 for diabetic macular edema and post-cataract surgery inflammation, OCS-02 for dry eye disease, and OCS-05 for acute optic neuritis [3] - The company is headquartered in Switzerland and operates in the U.S. and Iceland, aiming to enhance patient health and quality of life globally [3]